Journal of Pharmaceutical Analysis (May 2024)

GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation

  • Jiani Zhong,
  • Hang Chen,
  • Qiming Liu,
  • Shenghua Zhou,
  • Zhenguo Liu,
  • Yichao Xiao

Journal volume & issue
Vol. 14, no. 5
p. 100917

Abstract

Read online

Atrial fibrillation (AF) is the most common cardiac arrhythmia. Many medical conditions, including hypertension, diabetes, obesity, sleep apnea, and heart failure (HF), increase the risk for AF. Cardiomyocytes have unique metabolic characteristics to maintain adenosine triphosphate production. Significant changes occur in myocardial metabolism in AF. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been used to control blood glucose fluctuations and weight in the treatment of type 2 diabetes mellitus (T2DM) and obesity. GLP-1RAs have also been shown to reduce oxidative stress, inflammation, autonomic nervous system modulation, and mitochondrial function. This article reviews the changes in metabolic characteristics in cardiomyocytes in AF. Although the clinical trial outcomes are unsatisfactory, the findings demonstrate that GLP-1 RAs can improve myocardial metabolism in the presence of various risk factors, lowering the incidence of AF.

Keywords